Biopharmaceutical company focused on developing vaccines for infectious diseases.
HilleVax, Inc. is a clinical-stage biopharmaceutical company dedicated to the development and eventual commercialization of innovative vaccines. At the forefront of its pipeline is HIL-214, a vaccine candidate based on virus-like particles designed specifically to prevent moderate-to-severe acute gastroenteritis caused by norovirus and related illnesses.
Originally known as MokshaCo, Inc., the company rebranded itself as HilleVax, Inc. in February 2021, marking a strategic shift towards focusing on vaccine development. Since its inception in 2019, HilleVax has rapidly advanced its scientific endeavors from early-stage research to clinical trials, aiming to address significant unmet medical needs in the field of infectious diseases.
Headquartered in Boston, Massachusetts, HilleVax operates within a dynamic biopharmaceutical landscape, leveraging cutting-edge technologies and innovative approaches to vaccine design. The company's mission is underscored by a commitment to delivering safe and effective vaccines that can make a meaningful impact on public health globally.
As it continues to progress through clinical development stages, HilleVax remains dedicated to advancing its pipeline, collaborating with research partners, and pursuing regulatory approvals that will enable the widespread availability of its novel vaccine candidates.